...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Bone >Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches
【24h】

Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: Combined and sequential approaches

机译：骨形成和反射治疗治疗绝经后骨质疏松症：组合和顺序方法

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Efficient therapies are available for the treatment of osteoporosis. Bisphosphonates and denosumab are the most commonly used antiresorptive therapies. Despite differences in the increase in bone mineral density seen with these drugs, the reductions in fracture risk are similar; 50-70%, 20%, and 40% for vertebral, non-vertebral and hip fractures, respectively. The bone-forming treatments; teriparatide and abaloparatide increase bone mineral density more than the antiresorptives and the reductions in fracture risk are 85% and 40-50% for vertebral and non-vertebral fractures, respectively, compared to placebo. The VERO study demonstrated a > 50% reduction in vertebral and clinical fractures in women treated with teriparatide compared to risedronate. The dual-action treatment; romosozumab leads to more pronounced increases in BMD than other treatment modalities and reduces the risk of vertebral and clinical fractures by 73% and 36% compared to placebo after 12 months and the sequential treatment regime; romosozumab for 12 months followed by alendronate reduced the risk of vertebral, non-vertebral and hip fractures by 48%, 20% and 38%, respectively compared to alendronate after 2-3 years.
机译：有效的疗法可用于治疗骨质疏松症。双膦酸盐和DeNosumab是最常用的反侧疗法。尽管用这些药物看到的骨矿物密度的增加差异，但骨折风险的减少是相似的;椎体，非椎骨和髋部骨折的50-70％，20％和40％。骨形成的治疗;与安慰剂相比，Teriparatide和Abaloparatide增加骨矿物质密度超过反射性，并且骨折风险的降低分别为椎体和非椎骨骨折的85％和40-50％。 Vero的研究表明，与Riedronate相比，用Teriparidide治疗的妇女治疗的妇女的椎体和临床骨折减少> 50％。双动作治疗;与其他治疗方式相比，罗米苏达烃与其他治疗方式相比，与其他治疗方式更明显，与其他治疗方案减少73％和36％的椎体和临床骨折的风险;罗马窦12个月，然后是结复蛋白的风险降低了48％，20％和38％的风险，分别在2-3岁后与阿仑膦酸盐相比。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号